New Human Health Strategy Focuses on Creation of Wound Care Hydrogel Containing Patented Enzyme

Kane Biotech Inc. (Winnipeg, Manitoba), is focusing on using their patented enzyme DispersinB®to create a wound care hydrogel. The ultimate goal of this development would be to remove bacteria biofilm to improve the efficacy of existing wound care treatments. Dr. Jeffrey Kaplan Assistant Professor in the Department of Oral Biology at the University of Medicine and Dentistry of New Jersey, now part of Rutgers University, discovered the benefits of the enzyme and has continued his work to develop the technology platform. 

Kane Biotech works to research, develop, and commercialize technologies and products that prevent and remove microbial biofilms, and ultimately reduce bacteria that could become more resistant to antibiotics, antimicrobial agents, disinfectants, and the host immune system due to the presence of biofilm. The goal of these anti-biofilm therapies is to allow provides to effectively treat wound infections. 

Click here to learn more.